TY - JOUR
T1 - Dehydroepiandrosterone supplementation in women with adrenal failure
T2 - Impact on twenty-four hour GH secretion and IGF-related parameters
AU - Christiansen, Jens Juel
AU - Gravholt, Claus Højbjerg
AU - Fisker, Sanne
AU - Svenstrup, Birgit
AU - Bennett, Paul
AU - Veldhuis, Johannes
AU - Andersen, Marianne
AU - Christiansen, Jens S.
AU - Jørgensen, Jens O.L.
PY - 2004/4/1
Y1 - 2004/4/1
N2 - OBJECTIVE: In women, GH secretion is strongly influenced by oestrogen status, whereas the role of androgens is unclear. We, therefore, examined GH secretory dynamics during low vs. normalized androgen levels in women with adrenal failure. PATIENTS: Ten females with adrenal failure (AF), mean age of 42 years (range 22-54 years). DESIGN: The effects of 8 days of oral dehydroepiandrosterone (DHEA; 50 mg/day) were studied in a double-blind placebo-controlled, cross-over design. A control group of healthy women was studied once without any treatment. MEASUREMENTS: Before and after each treatment period, blood was sampled for measurement of androgens, IGF-I, IGFBP-3 and GHBP. A 24-h GH profile with measurements every 20 min was performed at the end of each period. RESULTS: DHEA supplementation normalized the mean circulating levels of testosterone and androgen precursors. The secretory pattern of GH was unaltered during DHEA [placebo vs. DHEA; half-life 22.83 ± 1.24 vs. 21.45 ± 1.19 (min), P = 0.429; pulse frequency 9.9 ± 0.7 vs. 10.5 ± 0.5 (/24 h), P = 0.502; total production rate 62.27 ± 13.44 vs. 52.61 ± 7.06 (μg/l/day), P = 0.317]. Subgroup analysis, however, indicated that DHEA treatment increased GH secretion in patients not receiving oestrogen (n = 5), whereas the opposite was observed among patients receiving exogenous oestrogen derivatives (n = 5). Compared to the control group (CON), GH half-life was longer in AF (half-life CON: 16.48 ± 0.91, P = 0.001). The additional features of GH secretion were similar. Unexpectedly, the levels of IGF-I, IGFBP-3 and GHBP were elevated in the patients as compared to controls, without significant effects of DHEA [AF vs. CON. IGF-I: 186 ± 20 vs. 144 ± 7 (μg/l), P = 0.04; IGFBP-3: 5196 ± 224 vs. 3687 ± 212 (μg/l), P = 0.001; GHBP: 2.27 ± 0.25 vs. 1.41 ± 0.13 (nmol/l), P = 0.002]. CONCLUSION: (1) Short-term DHEA administration in women with adrenal failure normalizes the circulating levels of androgens without uniformly affecting the GH-IGF axis; (2) The observation that exogenous oestradiol may mask a stimulatory effect of DHEA on GH secretion merits future investigation.
AB - OBJECTIVE: In women, GH secretion is strongly influenced by oestrogen status, whereas the role of androgens is unclear. We, therefore, examined GH secretory dynamics during low vs. normalized androgen levels in women with adrenal failure. PATIENTS: Ten females with adrenal failure (AF), mean age of 42 years (range 22-54 years). DESIGN: The effects of 8 days of oral dehydroepiandrosterone (DHEA; 50 mg/day) were studied in a double-blind placebo-controlled, cross-over design. A control group of healthy women was studied once without any treatment. MEASUREMENTS: Before and after each treatment period, blood was sampled for measurement of androgens, IGF-I, IGFBP-3 and GHBP. A 24-h GH profile with measurements every 20 min was performed at the end of each period. RESULTS: DHEA supplementation normalized the mean circulating levels of testosterone and androgen precursors. The secretory pattern of GH was unaltered during DHEA [placebo vs. DHEA; half-life 22.83 ± 1.24 vs. 21.45 ± 1.19 (min), P = 0.429; pulse frequency 9.9 ± 0.7 vs. 10.5 ± 0.5 (/24 h), P = 0.502; total production rate 62.27 ± 13.44 vs. 52.61 ± 7.06 (μg/l/day), P = 0.317]. Subgroup analysis, however, indicated that DHEA treatment increased GH secretion in patients not receiving oestrogen (n = 5), whereas the opposite was observed among patients receiving exogenous oestrogen derivatives (n = 5). Compared to the control group (CON), GH half-life was longer in AF (half-life CON: 16.48 ± 0.91, P = 0.001). The additional features of GH secretion were similar. Unexpectedly, the levels of IGF-I, IGFBP-3 and GHBP were elevated in the patients as compared to controls, without significant effects of DHEA [AF vs. CON. IGF-I: 186 ± 20 vs. 144 ± 7 (μg/l), P = 0.04; IGFBP-3: 5196 ± 224 vs. 3687 ± 212 (μg/l), P = 0.001; GHBP: 2.27 ± 0.25 vs. 1.41 ± 0.13 (nmol/l), P = 0.002]. CONCLUSION: (1) Short-term DHEA administration in women with adrenal failure normalizes the circulating levels of androgens without uniformly affecting the GH-IGF axis; (2) The observation that exogenous oestradiol may mask a stimulatory effect of DHEA on GH secretion merits future investigation.
UR - http://www.scopus.com/inward/record.url?scp=1842784911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842784911&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.2004.01998.x
DO - 10.1111/j.1365-2265.2004.01998.x
M3 - Article
C2 - 15049961
AN - SCOPUS:1842784911
SN - 0300-0664
VL - 60
SP - 461
EP - 469
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 4
ER -